Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 1/20 | 0.53 |
| ▸ | GSK3A | P49840 | 2/20 | 0.52 |
| ▸ | GSK3B | P49841 | 2/20 | 0.52 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.52 |
| ▸ | AHR | P35869 | 1/20 | 0.52 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.52 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 7/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | RAD52 | P43351 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1748903 | 0.88 | GSK3A (0.53) | IGF1RGSK3AGSK3BNR1I2AHR | |
| SCHEMBL4224401 | 0.86 | GSK3A (0.52) | IGF1RGSK3AGSK3BNR1I2AHR | |
| SCHEMBL1751684 | 0.85 | GSK3A (0.51) | IGF1RGSK3AGSK3BNR1I2AHR | |
| SCHEMBL4566417 | 0.84 | GSK3A (0.45) | IGF1RGSK3AGSK3BNR1I2AHR | |
| SCHEMBL4223368 | 0.84 | GSK3A (0.51) | IGF1RGSK3AGSK3BNR1I2AHR | |
| SCHEMBL4052746 | 0.81 | IGF1R (0.51) | IGF1RGSK3AGSK3BNR1I2AHR | |
| SCHEMBL4052739 | 0.81 | IGF1R (0.51) | IGF1RGSK3AGSK3BNR1I2AHR | |
| SCHEMBL4227109 | 0.81 | IGF1R (0.51) | IGF1RGSK3AGSK3BNR1I2AHR | |
| SCHEMBL4228405 | 0.74 | HSD17B10 (0.45) | GSK3AGSK3BNR1I2AHRCDK5 | |
| SCHEMBL656365 | 0.72 | POLB (0.51) | IGF1RCDK5CDK5R1MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383634-B2 | Methods of treatment using heteroaryl compounds and compositions thereof | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-02-26 | — | — | US | disclosed |
| US-20110224217-A1 | METHODS OF TREATMENT USING HETEROARYL COMPOUNDS AND COMPOSITIONS THEREOF | SIGNAL PHARMACEUTICALS, LLC | 2011-09-15 | — | — | US | disclosed |
| US-7968556-B2 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2011-06-28 | — | — | US | disclosed |
| US-20090042890-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224217-A1 | METHODS OF TREATMENT USING HETEROARYL COMPOUNDS AND COMPOSITIONS THEREOF | JAK2, CHEK2, PHKG1 | IGF1R 576/4885GSK3A 348/4885GSK3B 336/4885 |
| US-20090042890-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | JAK2, CHEK2, SRC | IGF1R 838/4885GSK3A 391/4885GSK3B 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.